Post by Boehringer Ingelheim

#NEWS: Bringing innovation from discovery to patients takes strong partnerships and sustained delivery. We have now advanced a third program rooted in our partnership with Oxford BioTherapeutics into the clinic, bringing the total to three clinical-stage programs, including obrixtamig, which has advanced to late-stage development. This progress shows the power of combining complementary expertise - from target discovery through to global development - to accelerate new treatment options for people facing difficult-to-treat cancers. Learn more: https://lnkd.in/e4XmuspK #PartneredInnovation #PrecisionMedicine #Oncology